Personalized Digital-Heart Technology for Ventricular Tachycardia Ablation Targeting in Hearts With Infiltrating Adiposity.

Circulation. Arrhythmia and Electrophysiology
Eric SungNatalia A Trayanova

Abstract

Infiltrating adipose tissue (inFAT) is a newly recognized proarrhythmic substrate for postinfarct ventricular tachycardias (VT) identifiable on contrast-enhanced computed tomography. This study presents novel digital-heart technology that incorporates inFAT from contrast-enhanced computed tomography to noninvasively predict VT ablation targets and assesses the capability of the technology by comparing its predictions with VT ablation procedure data from patients with ischemic cardiomyopathy. Digital-heart models reflecting patient-specific inFAT distributions were reconstructed from contrast-enhanced computed tomography. The digital-heart identification of fat-based ablation targeting (DIFAT) technology evaluated the rapid-pacing-induced VTs in each personalized inFAT-based substrate. DIFAT targets that render the inFAT substrate noninducible to VT, including VTs that arise postablation, were determined. DIFAT predictions were compared with corresponding clinical ablations to assess the capabilities of the technology. DIFAT was developed and applied retrospectively to 29 ischemic cardiomyopathy patients with contrast-enhanced computed tomography. DIFAT ablation volumes were significantly less than the estimated clinical ablatio...Continue Reading

References

Jul 1, 1982·The American Journal of Clinical Nutrition·G A BorkanJ E Silbert
Dec 17, 2008·Journal of Cardiovascular Computed Tomography·Aidan R RaneyStephanie Channual
May 16, 2009·JACC. Cardiovascular Imaging·Yasutaka IchikawaHajime Sakuma
May 1, 2010·Journal of Cardiovascular Computed Tomography·Dorinna D MendozaW Guy Weigold
Jun 1, 2012·Annals of Biomedical Engineering·J D BayerN A Trayanova
Nov 6, 2012·Journal of the American College of Cardiology·Miki YokokawaFrank Bogun
Feb 13, 2016·Journal of the American College of Cardiology·Francis E MarchlinskiAnil K Bhandari
May 11, 2016·Nature Communications·Hermenegild J ArevaloNatalia A Trayanova
Dec 20, 2017·Circulation·Saagar MahidaHubert Cochet
Mar 9, 2019·Nature Biomedical Engineering·Adityo PrakosaNatalia A Trayanova
Mar 30, 2019·Journal of the American College of Cardiology·William G StevensonJohn L Sapp
Aug 21, 2019·Nature Biomedical Engineering·Patrick M BoyleNatalia A Trayanova
Oct 8, 2019·Heart Rhythm : the Official Journal of the Heart Rhythm Society·Julie K ShadeNatalia A Trayanova
Dec 21, 2019·JACC. Clinical Electrophysiology·Gustavo S GuandaliniFrancis E Marchlinski
Mar 5, 2020·Journal of the American College of Cardiology·Roderick TungShulin Wu

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antiarrhythmic Agents: Mechanisms of Action

Understanding the mechanism of action of antiarrhythmic agents is essential in developing new medications as treatment of cardiac arrhythmias is currently limited by the reduced availability of safe and effective drugs. Discover the latest research on Antiarrhythmic Agents: Mechanism of Action here.

Anti-Arrhythmic Drug Therapies

Anti-arrhythmic drugs are used to prevent abnormal heart rhythms. These medications are used in conditions including, ventricular tachycardia, ventricular fibrillation and atrial fibrillation. Discover the latest research on anti-arrhythmic drug therapies here.

Cardiomyopathy

Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.